Compare Robinhood Markets, Inc. (HOOD) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Nuvalent Inc — how do they compare? Robinhood Markets, Inc. trades at $104.41 (market cap $95.49B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Robinhood Markets, Inc. is far larger — about 9.7× Nuvalent Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| HOOD | NUVL | |
|---|---|---|
Market Cap | $95.49B | $9.81B |
Sector | Technology | Technology |
52-Week High | $152.46 | $123.96 |
52-Week Low | $65.16 | $72.16 |
Enterprise Value | $96.69B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood Markets (HOOD) trades at $106.36, up 6.4% over 24 hours, with technical indicators showing a bearish trend near resistance at $106. The company reported strong 2025 results with $4.47B revenue and $1.88B net income, though Q1 2026 EPS missed expectations. Recent news highlights expansion into blockchain infrastructure and institutional stake changes.
Outlook remains mixed: analyst consensus is bullish with a $118.07 price target, but risks include earnings volatility and competitive pressures. The stock's high P/E of 48.19 suggests premium valuation, requiring sustained growth to justify current levels amid bearish technical signals.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
